TRADE BRIEF — ELV (Elevance Health)

Generated at signal price $412.10

SETUP

ELV cleared the $410.46 breakout level on volume running 2.77x average, opening at $401.75 and pushing to a high of $418.20 before settling near $412. The move off the prior close of $398.69 represents a clean 3.38% surge with price now trading above the breakout level and holding. The 52-week range of $274.84 to $436.24 puts current price in the upper half, with roughly $24 of room before retesting the annual high. The candle structure shows buyers absorbed the open and drove higher with conviction.

CATALYSTS

The April 2025 earnings beat of $11.97 vs $11.38 estimated (plus 5.2%) is a meaningful fundamental driver. ELV's low beta of 0.71 makes it attractive in uncertain macro environments. Managed care names are benefiting from stabilizing Medicaid redetermination headwinds and potential tailwinds from government cost-cutting pressures pushing patients toward private plans. Insider buying across multiple executives and directors over recent months adds incremental confidence.

RISKS

The signal quality score of 50/100 is average, flagging that entry is not early in the move. The October 2024 earnings miss of 13.3% was significant and a reminder that medical cost ratio surprises can hit this name hard. A dividend figure showing 172% is almost certainly a data anomaly and should be verified before sizing up. No analyst rating is provided, leaving institutional sentiment unclear. Next earnings are not until October 2026, so there is no near-term catalyst to force a move to target. Stop at $402.55 is tight at roughly 2.3% below current price given the intraday range.

CONVICTION: Medium — The volume surge and earnings beat are real positives, but the middling signal quality score and extended entry relative to the candle high limit upside confidence at this level.